Treatment of central type lung cancer by combined cryotherapy: Experiences of 47 patients

详细信息    查看全文

• 作者：Zhang Zhikai ; Niu Lizhi ; Zhou Liang ; Zeng Jianying ; Yao Fei ; Chen Jibing ; Li Jialiang ; Xu Kecheng
• 关键词：Central type lung cancer ; Percutaneous cryosurgery ; Airway stenting ; Endobronchial cryosurgery
• 刊名：Cryobiology
• 出版年：2013
• 出版时间：October, 2013
• 年：2013
• 卷：67
• 期：2
• 页码：225-229
• 全文大小：676 K

文摘

Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5 cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3 days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2 weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8 ¡À 4 months) was shorter than that for tracheal wall (13 ¡À 6 months, P < 0.05) and extratracheal (14 ¡À 8 months, P < 0.01) tumors. The PFS of NSCLC (11 ¡À 5 months) was significantly longer than that of SCLC (4 ¡À 2 months, P < 0.0001). The PFS of medium or well differentiated CTLC (15 ¡À 8 months) was significantly longer than that of poorly differentiated CTLC (7 ¡À 3 months, P < 0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type.